|1.||Shariat, Shahrokh F: 16 articles (11/2014 - 12/2003)|
|2.||Lotan, Yair: 13 articles (11/2014 - 05/2005)|
|3.||Casella, Roberto: 9 articles (03/2008 - 12/2003)|
|4.||Svatek, Robert S: 7 articles (11/2014 - 04/2006)|
|5.||Stenzl, Arnulf: 7 articles (01/2014 - 01/2009)|
|6.||Karakiewicz, Pierre I: 7 articles (03/2012 - 05/2005)|
|7.||Sagalowsky, Arthur I: 7 articles (07/2009 - 03/2004)|
|8.||Schwentner, Christian: 6 articles (01/2014 - 01/2012)|
|9.||Grossman, H Barton: 6 articles (10/2011 - 02/2005)|
|10.||Boman, Hans: 5 articles (03/2008 - 01/2002)|
|1.||Urinary Bladder Neoplasms (Bladder Cancer)
04/01/2000 - "The purpose of this study was to evaluate, from the perspective of the Quebec health system, the cost and cost-efficacy of using NMP22 compared with the currently recommended monitoring procedure following a transurethral resection of a bladder tumor (TURBT). "
12/01/2008 - "Combining NMP22 with malignant or suspicious cytological result improved sensitivity for the detection of bladder cancer but with a major decrease in specificity, suggesting a potential role in screening rather than diagnosis."
03/01/2006 - "The NMP22 BladderChek test is an in vitro qualitative test that is easily available and cheap; it can be performed by a urologist in the office and results can be interpreted within 30 min. The NMP22 test is superior to cytology for all grades and stages in the detection of recurrence in patients with a history of superficial bladder cancer. "
03/01/2011 - "The NMP22 test may be considered a new gold standard for the assessment of patients with known or suspected bladder cancer."
03/01/2011 - "This study aimed to compare the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of urine cytology, BladderChek® nuclear matrix protein-22 (NMP22) and UroVysion™ fluorescence in situ hybridization (FISH) tests in patients with newly diagnosed bladder cancer, those with recurrent bladder cancer, and those with bladder cancer but in remission during surveillance. "
03/01/2004 - "[The clinical efficacy of Bladder Chek NMP22 in urothelial cancer]."
08/01/2002 - "False-positive results on BTA Stat in 2 of 22 patients (9%), on NMP22 in 2 of 25 (8%), on 486p3/12 in 3 of 11 (27%) and on Lewis X in 4 of 43 (9.3%) were associated with tumor recurrence. "
07/01/2001 - "Awareness and exclusion of the categories of false-positive results can increase the specificity and positive predictive value of NMP22, enhancing the clinical use of this urinary tumor marker."
07/01/2003 - "Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer."
09/01/2002 - "This study was designed to evaluate the significance of NMP22 in TCCU as a new urinary tumor marker and its influence factors. "
|3.||Transitional Cell Carcinoma
09/01/1999 - "NMP22 and BTA stat test results represented significant improvement over urinary cytology for detection of transitional cell carcinoma. "
02/01/1998 - "NMP22 values represented significant improvement over urinary cytology for detection of transitional cell carcinoma. "
10/01/1996 - "Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). "
10/01/1996 - "Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. "
01/01/1997 - "We provide a summary of the studies completed with the immunoassay for urinary NMP22 as an indicator for the presence of transitional-cell carcinoma and compare the results with those obtained using other screening modalities."
02/01/2002 - "False-positive results of the NMP22 test due to hematuria."
11/01/2014 - "It was associated with age greater than 65 (11.1% vs 4% of patients, p = 0.012), male gender (10.1% vs 2%, p = 0.003), white ethnicity (9.2% vs 3.1%, p = 0.016), gross hematuria (9.9% vs 2.5%, p = 0.005), positive NMP22 (37% vs 3.7%, p <0.001) and positive cytology (83.3% vs 3.9%, p <0.001). "
03/01/2011 - "In addition to the regularly performed check for hematuria and urine cytology, the markers NMP22, UroVysion™ and survivin were performed in voided urine samples of the participants. "
07/01/2010 - "Markers such as the Urovysion FISH assay and the NMP22 BladderChek test are approved for surveillance and detection in patients with hematuria. "
04/01/2008 - "Group 2:15 patients with history of hematuria underwent cystoscopy and NMP22 BladderChek. "
05/01/2012 - "For the primary diagnosis of bladder carcinoma, neither the UBC rapid nor the NMP22 BladderChek POC test systems are sensitive to the presence of blood in the urine, whereas BTA stat consistently yields false-positive results due to cross-reactivity to macrohaematuria and microhaematuria up to a density of 150 erythrocytes/μl, thus this system should not be employed for this examination."
09/01/2012 - "uRNA and Cxbladder showed improved sensitivity for the detection of urothelial carcinoma compared to the NMP22 assays. "
10/01/2013 - "The aim of this study is to evaluate the diagnostic values of the fluorescence in situ hybridization (FISH), NMP22 BladderChek, and liquid-based cytology (LBC) in the detection of bladder urothelial carcinoma (UC). "
11/01/2014 - "A logistic regression model to predict urothelial bladder carcinoma was also developed to compare the performance of clinical data with and without adding NMP22 and urinary cytology. "
10/01/2013 - "Comparison of fluorescence in situ hybridization, NMP22 bladderchek, and urinary liquid-based cytology in the detection of bladder urothelial carcinoma."
|1.||nuclear matrix protein 22
|3.||Telomerase (Telomerase Reverse Transcriptase)
|4.||Biological Tumor Markers (Tumor Markers)
|6.||formycin diphosphate (FDP)
|9.||Biological Markers (Surrogate Marker)
|10.||Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)
|1.||Urinary Diversion (Ileal Conduit)